Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLYMPIA-3: odronextamab plus CHOP versus rituximab plus CHOP in previously untreated DLBCL
MOH_2023-11-21_013066Phase 3Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of odronextamab in diffuse large B-cell lymphoma (DLBCL) (5 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Safety and tolerability in Part 1 and Efficacy in Part 2. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
odronextamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2023-11-21_013066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-11-21_013066.